Immutep Limited income statement PRRUF

Annual Quarterly

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2025
Jun 30, 2025
FY 2024
Jun 30, 2024
FY 2023
Jun 30, 2023
FY 2022
Jun 30, 2022
FY 2021
Jun 30, 2021
FY 2020
Jun 30, 2020
FY 2019
Jun 30, 2019
FY 2018
Jun 30, 2018
Weighted average shares, basic
1,456
+21.2%
1,201
+34.6%
892
+5.1%
849
+42.7%
595
+44.1%
413
+19.0%
347
+26.1%
275
Weighted average shares, diluted
1,456
+21.2%
1,201
+34.6%
892
+5.1%
849
+42.7%
595
+44.1%
413
+19.0%
347
+26.1%
275
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
IMMP (Nasdaq), PRRUF (OTC)
Fiscal year ends
June 30
Incorporated in
Australia
Headquarters
Sydney,, Australia
SEC filer status
Accelerated filer
SEC CIK
1506184
Former names
Prima BioMed Ltd (until Dec 1, 2017)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.